ODF: A potential formulation strategy for special patient populations
There is an increasing need of developing new drug delivery platforms to address the needs of special patient populations. For example, the paediatric patient requires the medicine dosage to be adequate to the constantly increasing body weight. As medicinal products containing the required dosage may not be available, the practice of splitting tablets, opening capsules, or mixing powders with foods or liquids may lead to dose inaccuracy and other consequences for the safety of the patient and the efficacy of the treatment (Visser et al., 2016) . Similarly, other populations may have specific needs with respect to medicine administration (Grimsrud et al., 2015; Slavkova and Breitkreutz, 2015; Stegemann et al., 2010) . Therefore, the development of drug delivery platforms that can help addressing the needs of specific patient populations is greatly needed.
Orodispersible films have been reported to contribute to an improved patient compliance by improving ease of administration and by not requiring water (Bala et al., 2013; Krampe et al., 2015) . Furthermore, ODFs offer a wide range of features that can be easily adapted to the needs of individual patients or patient populations.
According to Borges and colleagues, patients suffering from dysphagia or subjected to an increased risk of chocking can benefit from the employment of ODF platforms for drug administration. As ODFs are inherently easy to administer, young and older patients can have access to a platform that can ensure a complete and precise dosing of medicines, minimising the risk of partial loss of actives due to tablet crushing or imprecise liquid administration.
Moreover, medicine administration to uncooperative patients can be facilitated by the adhesion of ODFs to the oral cavity, therefore preventing the medicine to be spit out. Other ODF features such as flexibility, portability, and stability can confer superiority to other dosage forms like orodispersible tablets or liquids (Borges et al., 2015a ) (Borges at al., 2015 vol I). Delivering actives via ODFs through oral mucosa, can lead to rapid dissolution and fastest onset of action (Ashraf and Sayeed, 2014; Choudhary et al., 2013) . Some examples of ODF products are commercially available for Alzheimer's disease (Donepezil -Labtech, Kyukyu Pharmaceuticals, Hexal Pharmaceuticals), emesis (Ondansetron -Monosol, Labtech, Aavishkar), schizophrenia (Olanzapine -Labtech, Hexal Pharmaceuticals), migraine (Zolmitriptan -Monosol, Labtech, NAL Pharma) etc. (Borges et al., 2015a) . The readers are referred to a recent review by Borges et al. for a comprehensive product list of oro-mucosal film based products that are registered, launched, under (pre-) clinical development or withdrawn/ discontinued.
The acceptability of ODFs was described in a recent paper considering the features of the final product including appearance, composition, taste and mouthfeel (Krampe et al., 2015) .
ODFs are considered to be age-appropriate oral dosage forms mainly with respect to its disintegration in the oral cavity upon administration without water. Furthermore, ODFs offer the possibility to implement taste masking technologies in order to minimise the averseness of the taste of the Active Pharmaceutical Ingredient (API). Mouthfeel and texture are also considered key characteristics potentially affecting the acceptability of ODFs, particularly with regards to the presence of residual particles following disintegration (Krampe et al., 2015) . Mouthfeel in the sensory evaluation of foods has been related to the primary role of the saliva function. A reduced salivary production could therefore alter the mouthfeel of a product in specific patient groups such as patients under treatment for HIV, or older patients subjected to polypharmacy (Gupta et al., 2006; López-Verdín et al., 2013; Stokes et al., 2013) . Other features like appearance, mucosal irritation, and API absorption are also considered relevant features to take into consideration when designing an ODF formulation (Krampe et al., 2015) .
In addition to the aforementioned ODF characteristics, other features could potentially positively or negatively affect the patient acceptability of the dosage form, and should be further explored. As proposed in Figure 1 , the handling, placement and disintegration of ODFs are key stages to identify the full product features with high potential impact on patient experience. For example, the "stickiness/adhesiveness" of the film potentially contributes to placement in the mouth and subsequently the overall mouthfeel of the product. Krampe and colleagues have referred to the "gummy" nature of the films after wetting as potentially contributing to the mouthfeel of the dosage form (Krampe et al., 2015) . Moreover, in the case of patients experiencing poor manual dexterity, poor hand sensitivity or reduced pinch strength (Stegemann et al., 2016) , high ODF stickiness may result in the inability to properly handle the dosage form. These properties are largely related to the intrinsic properties of the carrier polymers, eg. hygroscopicity and interfacial attributes. The ODF formulation is designed to disintegrate fast once placed in the mouth. Wettability, disintegration, and dissolution time of the film may change depending on the saliva production rate of the user.
These parameters are considered to govern the performance of ODF drug products.
Therefore, in the case of patients affected by severely impaired saliva production (dry mouth syndrome), ODFs may not be the dosage form of choice for drug administration. 
Formulation, process and quality considerations of orodispersible films products
ODF products are conventionally manufactured via film casting of solution, suspension or melt using diverse technologies such as solvent casting, semisolid casting, rolling, coating and hot melt sheet extrusion (Borges et al., 2015a; Krampe et al., 2015) . In these cases, the API(s) is/are dispersed in a feedstock with the suitable excipients, formulation and/or process aids and processed to yield films of desired dimensions and mechanical properties.
Typically, therefore, ODF formulations have the structure of a matrix-based composite film.
The current co-matrix formulation and process platforms intrinsically harbour some limitations in terms of content uniformity and the ability to combine and diversify doses because the final formulation is homogeneous. Furthermore, due to their moderate size and thickness ODFs can typically be loaded only with limited drug concentrations per unit volume and surface area (Bala et al., 2013) . Therefore, oral films are not generally suitable for treatments requiring high dosages, although up to 50% drug loading in an ODF (Gas-X Strips ® , Novartis) has been reported (Siddiqui et al., 2010) .
The ODF design process should take several parameters into consideration: therapeutic target, patient population, safety, appropriateness and compatibility of API and excipients, processability of the polymeric mixture, impact on stability, physicochemical and mechanical characteristics of the final product, residual solvent/water content, drug release profile, packaging, and acceptability to the end user. Each pharmaceutical development stage can have a deep impact on the quality of the final product and must be carefully evaluated.
Manufacturing technologies
The most widespread technologies for ODF manufacture include solvent casting and semisolid casting as broadly described by Hoffmann and colleagues (Hoffmann et al., 2011a) .
These generally include feed stock of drug-excipient solution or suspension in aqueous and/or non-aqueous media. The use of organic solvents in solvent casting can improve the solubility of some APIs. Conversely, residual amounts of solvents could remain in the final product. Other manufacturing parameters, such as casting solution homogeneity, stability and film thickness, must be accurately monitored to ensure a smooth process.
Hot melt extrusion (HME) offers the advantage of a solvent-free process for ODF manufacturing (Palem et al., 2016 (Palem et al., , 2013 Park et al., 2015; Repka et al., 2003) . Yet, poor availability of suitable polymers and high temperatures may pose stability issues to the active (Hoffmann et al., 2011) . HME is a continuous manufacturing process. water content of the feed, viscosity, melt temperature) is the one of the key determinants of cooling/ drying time and therefore the entire process efficiency. On the other hand, the required size of the strip varies with the (personalised) dose, which can complicate primary packaging (eg. different pouch sizes and sealing times).
General formulation principles
The basic structure of oral films is a polymeric matrix. Typical polymeric carriers used in ODF manufacturing include cellulose, starches, gums and polysaccharides, proteins, and semi-synthetic or synthetic pharmaceutical grade polymers (Borges et al., 2015b) . Carrier polymer selection prerequisites for ODF formulations include solubility in water and/or diverse processing solvents, film forming properties, compatibility with wide range of APIs, safety and availability of different molecular weights/ degrees of substitution (Moritz, 2006) .
Depending on the physical and chemical properties of polymers or mixtures of polymers and the quality target product profile, the processability can be either favoured or impeded. For example, highly viscous polymer mixtures in melt extrusion lead to difficulty in processing.
In this respect, it is common practice to incorporate some plasticisers in the formulation. In addition surfactants are used to enhance solubility of poorly soluble drugs as well as the wettabilityof ODFs (Hoffmann et al., 2011a) .
Some small fractions of other functional excipients such as humectants and/or saliva stimulating agents, sweeteners, oro-mucosal permeation enhancers and trace colouring/flavouring agents are used (Hoffmann et al., 2011a) . The impact of each component to the final product should be evaluated during development. Therefore, the selection of film forming polymers should result in a balanced choice ensuring good processability yet possessing the desired film characteristics, most importantly in terms of in vitro and in vivo pharmaceutical performance and stability.
Quality aspects of the final product
In the absence of regulatory guidelines and due to the novelty of the dosage form, typical film potential Critical Quality Attributes (pCQA) have been described in recent publications (Borges et al., 2015a; Irfan et al., 2015) . Oral films should have appropriate mechanical strength to endure both the stress of the manufacturing pipeline, and folding during postproduction, while maintaining the targeted disintegration and drug release profile.
Mechanical characterisation studies should include measurement of thickness, tensile strength, elongation at break, tear resistance, folding endurance, and Young's modulus (Irfan et al., 2015) . Stability during all manufacturing stages must be carefully studied beforehand and monitored throughout. Particular attention should be paid to unintended or uncontrolled chemical reactions between active and excipients, physical property modifications due to high temperatures, and interactions between films and packaging material.
The drug release profile is another fundamental quality aspect for all types of orally administered films. How fast the film disintegrates, and the rate at which the drug is being released classifies the type of film being produced. With respect to disintegration and dissolution characterisation, a range of different dissolution/disintegration testing is available, although there is currently no harmonised approach towards the utilisation of a standard methodology. Due to the lack of specific guidelines, USP 1 or 2 dissolution apparatus is currently used as standard assays, although several criticisms have been made to the high volumes of dissolution/disintegration media employed (Garsuch and Breitkreutz, 2010) . manufacturing opportunity for personalised ODF manufacture (Cheow et al., 2015; Genina et al., 2013b; Sandler et al., 2011; Vakili et al., 2015) . Current studies are being conducted on the application of the inkjet printing technology to produce dose-flexible oral films (Alomari et al., 2014) . A wide diversity of finished solid oral dosage forms such as tablets, hard/soft gelation capsules can act as the substrate for printing (Boehm et al., 2015 (Boehm et al., , 2014 . For example, the surrogate technology of dispensing drug solutions or suspensions into placebo tablets was developed and readied for commercial manufacturing by GlaxoSmithKline (GSK) for highly potent actives (Clarke et al., 2012) . Since ODFs are the topic of this article, discussion in this direction has been excluded.
Precise and accurate dispensing of very small doses (pico to micro liter) is achievable by printing technology. Small volumes of drugs in liquid can be dispensed on-demand onto the film surface to ensure a precise therapeutic drug dose to be delivered to the patient. Inkjet printing technologies, resolution/ accuracy, scale, throughput, speed etc. have significantly evolved over the last decade (Derby, 2010; Sowade et al., 2016) .
Inkjet printing technology could be also used for pharmaceutical printing of multiple drugs onto a single substrate, ensuring drug compatibility, dose precision, and multiple medicationrelated issues . The therapeutic areas where inkjet-printed orodispersible film (IJ-ODFs) can potentially improve the ease of administration include pathologies where the patient experiences difficulty in self-medicating (severe psychological and neurological disorders), and/or difficulty in swallowing (severe neurodegenerative disorders causing swallowing difficulties). Therefore, uncooperative/ cognitively impaired, and dysphagic patients are major populations that can benefit from rapidly dissolving IJ-ODFs (Abdelbary et al., 2014). Furthermore, fast drug-releasing IJ-ODFs design can be further explored for managing emergency conditions that require rapid onset of action of the administered drug (Karki et al., 2016) , such as anaphylactic shock, congestive heart failure and sudden epileptic seizure, breakthrough pain and so on (Alayoubi et al., 2016) . The superiority of the drug release performance and medication efficiency of IJ-ODFs against traditional (pre) drug-loaded ODF is subject to further verification. IJ-ODFs, currently under development, can better address conditions requiring high dosage precision (Peck, 2015) , fixed dose combinations (FDC), by printing physicochemically interacting actives and excipients spatially as separate drops, and low dosage treatments (Bala et al., 2013; Preis et al., 2015) .
Regulation of drop size, printing pattern and density, etc. can modify the concentration of drug printed on a single film with a very high precision (Singh et al., 2010) . Further, the opportunity of printing specific patterns could serve as a useful form of identification of the specific medicinal preparation, especially for patients subjected to polypharmacy . The technology is still in a developing phase and readying towards compliance to the Good Manufacturing Practice (GMP) requirements for commercial-scale personalised pharmaceutical dosage manufacturing (Nallan et al., 2014) . More precisely, selection of printer material compatible with printing ink, development of cleaning and process validation protocols are important issues to be addressed. Similarly to the more recent 3D printing technology (Ventola, 2014) , the Inkjet printing platform could find applicability in the pharmacy setting. A personalised orodispersible film can be printed on-site by the pharmacist in order to respond to the needs of the individual patient (Alomari et al., 2014; Lind et al., 2016) . For instance, the required therapeutic dose can be adjusted on-site in particular benefitting paediatric patients.
Inkjet printing on ODFs: A case study
An exciting advancement in developing understanding of actives printed onto ODFs to produce personalised dosage forms has been described in a recent publication (Planchette et al., 2015) . A non-contact printing system that incorporates complementary inkjet technologies (piezoelectric actuator or solenoid valve) was utilised (Figure 2 ). Based on this approach, a wide range of inks including solutions of physicochemically diverse APIs, polymeric nano-suspensions and excipient coating solutions were successfully printed. The printing process of these diverse inks onto different types of commercial oral ODF placebos and customised films were optimised to avoid substrate damage (defects, holes, tears).
Morphological analysis of the printed surface clearly showed dependence on the ODF type used (Figure 3) . A consistent dispensing of drugs with a volumetric deviation of less than ± 2 % has also been achieved. 
Inkjet printing for personalised ODF manufacturing: unmet needs
Inkjet printing technology definitely requires further scientific efforts before the pharmaceutical drug delivery community embraces personalised dosage manufacturing.
Engineering solutions to allow the diverse range of benchtop printers, currently used in research and development (R&D) applications, up to GMP compliant industrial scale processing is the biggest challenge to successful pharmaceutical implementation.
Formulation aids (e.g. surfactants, crystallisation inhibitors, preservatives etc.) and process aids (e.g. viscosity modifiers, co-solvents etc.) can improve the specific printability parameters of drug-containing ink solutions such as surface tension and viscosity as well as final properties of the printed dosage forms (drug distribution and stability) (Di Risio and Yan, 2007; Genina et al., 2012; Wickström et al., 2015) . For sufficient loading of poorly soluble drugs, the ink formulations needs to be modified accordingly (non-aqueous solutions, nano-suspensions, lipidic formulations) (Williams et al., 2013) . Nucleation and crystal growth, Ostwald ripening in supersaturated solutions/ suspensions of poorly soluble drug can commence during feeding or during dispensing (nozzle tips). Inkjet printing using excipient stabilised aqueous nano-crystalline APIs as an ink and ODF as a substrate is currently sought after as a viable alternative to fabricate individualised dosage form of poorly soluble drug (Cheow et al., 2015; Hilgert et al., 2014) .
Beyond ink formulation, various inkjet printing related factors such as satellite drops, nozzle clogging, fast evaporation of volatile solvents, coffee ring effect have been an ongoing academic and industry R&D topic (Deegan et al., 1997; Hoath et al., 2008 Hoath et al., , 2012 Reis et al., 2005; Stringer and Derby, 2010) . For example, an empirical effort to validate the regime of fluid "jettability" has been described by Kuang and colleagues in 2014 (Nallan et al., 2014) . Now, the challenge is to translate this fundamental understanding towards advancing IJ-ODF platforms. Figure 4 illustrates potential ink formulation parameters and printing process parameters that can be critical in obtaining the desired quality attributes of the printed ODF dosage forms. 
Importance of ODF substrate for inkjet printing
Following the optimisation of ink formulation and printing process, the substrate properties are of utmost importance to meet the requirements for desirable product properties (Daly et al., 2015) . ODFs as a printing substrate should be developed with consideration given to incompatibilities with the potential ink components (drug, solvent, additives) (Genina et al., 2013; Preis et al., 2015; Raijada et al., 2013) . Poorly soluble drugs are normally challenging to incorporate in a water-soluble substrate without sufficient molecular miscibility and interfacial interactions. Nucleation and crystal growth on thin films are dominated by surface mobility with much faster kinetics than in bulk (Soutari et al., 2012) . Further studies on interfacial crystallisation will give some insight about the best strategy to adopt in order to predict and control the post-deposition of API morphology (H.-Y. . Along with substrate chemistry, modifying film microstructure (such as porosity, inter-connectivity) can be an alternatives to enhance drug loading and confine crystal growth, provided costeffectiveness and stability (Genina et al., 2013; Sandler et al., 2011) .
Product quality control and analysis
Process monitoring and control in terms of content uniformity and compositional homogeneity in the printed dosage forms is one of the key issues to be addressed for IJ-ODF for quantification of two APIs in the printed dosage form (Palo et al., 2016) . To this end, hyperspectral (Near Infrared, Raman, Terahertz spectroscopy, Raman spectroscopy and chemical imaging etc.) imaging holds immense potential for developing the analytical method for API assay and distribution in ODF films (Vakili et al., 2015b; Edinger et al., 2017) . Novel analytical tools such as optical coherence tomography and interferometry can provide fast and non-invasive analysis of printed layer thickness, surface roughness/deformation created via solvent evaporation, the degree of adherence of printed drops with the substrate as well as spatial distributions . Newman and colleagues recently employed Second Harmonic Generation (SHG) microscopy-guided synchrotron powder X-ray diffraction to detect 100 ppm crystalline ritonavir in a hydroxypropyl methylcellulose (HPMC) matrix (Newman et al., 2015) , while SHG microscopy-coupled confocal Raman spectroscopy enabled analysis of trace crystallites of paclitaxel in lyophilized Abraxane powder . Such analyses on printed films probably offer solid-state distribution in printed dots and their homogeneity (Chowdhury et al., 2014) .
Inkjet printing for individualised ODF form: S.W.O.T. analysis
Upgrading industrial-scale inkjet printing for pharmaceutical ODF manufacturing under a strictly regulated environment requires significant development effort and capital investment.
The aforementioned points and the need for dedicated downstream packaging for printed ODFs are considered in a strengths, weaknesses, opportunities and threats (S.W.O.T.) benchmark analysis for this platform, as presented in Table 1 . 
Strengths Weaknesses
 Capability of precise dosing to deliver micro-to nano-scale drug loading 
Polymeric ODF manufacturing by drop printing of molten ink formulation
An approach similar to solvent-based (inkjet) printing for molten ink formulations is being devolved by Reklaitis and colleagues (Reklaitis, n.d.; Hirshfield et al., 2014) . Briefly, dropon-demand (DoD) printing technology is used to deposit molten formulation drops onto edible films. As an example, a recent case study published by Içten and colleagues is discussed (Içten et al., 2015a) . Hot melts of naproxen (NAP) and poly (ethylene glycol) (PEG) or Pluronic were deposited with high dosing reproducibility onto HPMC-PEG 400 films. The process was developed in a semi-continuous operation mode. The organic solvent, API and polymer mixture was heated above its melting temperature and pumped through a DoD positive displacement pump. Temperature regulation was extended to the whole system including reservoirs, tubing, and nozzles. The drops were formed by the application of a pressure pulse upstream of the nozzle. In order to monitor the process, a camera equipped with motor sensors was able to estimate accurately the drop volume and the formation of satellite drops. After ink deposition, the formulation was assessed for its drug dissolution profile, reproducibility of dosage amounts, and physical form of NAP after printing.
The drug remained stable as no degradation peaks were detected.. X-Ray diffraction studies of showed that the NAP completely crystallized into the starting polymorphic form after deposition irrespective of formulation. The differences in the rate and extent of dissolution were associated to the polymeric carrier in two formulations. Drug dosage was consistent with the number of drops deposited at a low standard deviation. The high drop placement precision and highly controllable drop volume makes this technology suitable for the manufacturing of solid dosage forms for high potency drugs. The same group has also recently published on the process control and automation of DoD and the impact of melt solidification temperature, drop size and cooling rates in tailoring the melt-crystallisation tendency and in vitro dissolution behaviour of the melt-printed formulations (H. Içten et al., 2015b Içten et al., , 2014 . Prasad and colleagues recently used an electrostatic API or formulation powder deposition approach on to the substrate film followed by subsequent coalesce of powder with substrate in infrared oven (Prasad et al., 2015) .
Conclusion and future direction
There is an increasing need for patient-centric formulations tailored for patient populations.
The drug product design should ensure safety and efficacy as well as patient acceptability and usability. The ODF platform is a promising technology broadening the options for developing and manufacturing drug products for distinct patient populations. The existing technical manufacturing challenges and the lack of consensus on the empirical definition of patient acceptability criteria limit the broader industrial investment on conventional and novel ODF technology. Collaborative approach of pharmaceutical industry, regulatory bodies and academia is required to pave the way towards optimising the quality attributes of ODFs both for industrial manufacturing and patient acceptability. In this perspective, future studies will be needed with the purpose of addressing the technical issues encountered by industrial partners and simultaneously match the geriatric-centric acceptability criteria suggested in this manuscript.
References
Abdelbary, A., Bendas, E.R., Ramadan, A. 
